A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors

Inclusion criteria

* Histologically or cytologically confirmed diagnosis of solid tumor malignancy. * 18 years old with ECOG of 0-1. * female subject who is not pregnant * Male subjects must agree to use contraception methods * Able to swallow and retain oral medication. * The subject will refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study. * QTcB or QTcF \< 470 msec. * Bilirubin = 1.5mg/dl, AST, ALT, ALP \<2X ULN in absence of malignant disease in the liver or \<5X ULN in case of liver involvement by the tumor. * Serum Creatinine \<1.5mg/dL Exclusion Inclusion: * The subject has received anticancer treatment. * The subject has participated in a clinical trial and has received an investigational product within 21 days. * The subject has known brain metastases. * The subject has uncontrolled intercurrent illness. * History of sensitivity to any of the study medications, or components. * The subject is known to be positive for the human immunodeficiency virus (HIV). * Subjects who have had partial or complete gastrectomy. * Pregnant females as determined by positive ß-hCG test at screening or prior to dosing. * Lactating females. * Unwillingness or inability to follow the procedures outlined in the protocol.